Coronavirus Disease 2019 (COVID-19), which is caused by SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2), has rapidly spread leading to a global pandemic.
Here, we combined
m
ultiple cross displacement
amplification (MCDA) with
C
RISPR-
C
as12a-based
d
etection to develop a novel diagnostic test
(MCCD) and applied for the diagnosis of COVID-19, called COVID-19 MCCD. The MCCD
protocol conducts reverse transcription MCDA (RT-MCDA) reaction for RNA templates
followed by CRISPR-Cas12a/CrRNA complex detection of predefined target sequences after
which degradation of a single-strand DNA (ssDNA) molecule confirms detection of the
target sequence. Two MCDA primer sets and two CrRNAs were designed targeting the opening
reading frame 1a/b (ORF1ab) and nucleoprotein (N) of SARS-CoV-2. The optimal conditions
include two RT-MCDA reactions at 63 °C for 35 min and a CRISPR-Cas12a/CrRNA
detection reaction at 37 °C for 5 min. The COVID-19 MCCD assay can be visualized on
a lateral flow biosensor (LFB) and completed within 1 h including RNA extraction (15
min), RT-MCDA reaction (35 min), CRISPR-Cas12a/CrRNA detection reaction (5 min), and
reporting of result (within 2 min). The COVID-19 MCCD assay is very sensitive and
detects the target gene with as low as seven copies per test and does not cross-react
with non-SARS-CoV-2 templates. SARS-CoV-2 was detected in 37 of 37 COVID-19 patient
samples, and nonpositive results were detected from 77 non-COVID-19 patients. Therefore,
the COVID-19 MCCD assay is a useful tool for the reliable and quick diagnosis of
SARS-CoV-2 infection.